Fianlimab and Cemiplimab vs Anti-PD1 Alone in Resectable Stage III and IV Melanoma * | University Hospitals

Skip to main content

Loading Results

We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Home
UH Research
Clinical Trials & Studies
Clinical Trials Search
Fianlimab and Cemiplimab vs Anti-PD1 Alone in Resectable Stage III and IV Melanoma

Find Clinical Trials & Studies

Back to Top